other material
confidence high
sentiment positive
materiality 0.85
Arrowhead reports Phase 1/2a data: ARO-INHBE + tirzepatide doubles weight loss in obese T2DM patients
ARROWHEAD PHARMACEUTICALS, INC.
- ARO-INHBE + tirzepatide (n=4) achieved -9.4% weight loss at week 16 vs -4.8% with tirzepatide alone; visceral fat -23.2% vs -7.4%.
- ARO-INHBE monotherapy: single dose reduced visceral fat -9.9% at week 16; two doses gave -15.6% placebo-adjusted at week 24.
- ARO-ALK7 is first RNAi to silence an adipocyte gene; mean ALK7 mRNA reduction -88% at 200 mg; visceral fat -14.1% at week 8.
- Both candidates generally well tolerated; no discontinuations; one unrelated SAE (limb abscess) in ARO-INHBE group.
- Company expects additional results from these ongoing Phase 1/2a studies later in 2026.